<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8929">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990715</url>
  </required_header>
  <id_info>
    <org_study_id>cl-sy-01-0093</org_study_id>
    <nct_id>NCT02990715</nct_id>
  </id_info>
  <brief_title>Evaluation of Check-Cap C-Scan System in Providing Structural Information and Detection of Polypoid Lesions</brief_title>
  <official_title>Evaluation of Check-Cap C-Scan System in Providing Structural Information and Detection of Polypoid Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ceck Cap Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ceck Cap Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the efficacy of Check-Cap's C-Scan System in
      providing structural information on colonic polypoid lesions and masses, as an adjacent tool
      to FIT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double Blind (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy</measure>
    <time_frame>6 months</time_frame>
    <description>Number of polyps detected by the capsulle system in variuos segements of the colon as compared with the results indicated in the report of the follow-up colonoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm, compared with Optical Colonoscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Polypoid Lesions</condition>
  <arm_group>
    <arm_group_label>1) Up to 25 patients with known polypoid lesions ≥10 mm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2) Up to 10 patients average risk CRC screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Check-Cap's C-Scan System</intervention_name>
    <description>To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy
To evaluate the safety of the C-Scan Capsule System procedure</description>
    <arm_group_label>1) Up to 25 patients with known polypoid lesions ≥10 mm</arm_group_label>
    <arm_group_label>2) Up to 10 patients average risk CRC screening</arm_group_label>
    <other_name>Colon capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at the age of 40-75 years old

          -  Subject provided signed informed consent

        Exclusion Criteria:

          -  Patients with advanced cancer or other life threatening diseases or conditions

          -  Subject with known history of dysphagia or other swallowing disorders

          -  Subject with known history of GI disease or symptoms, such as: Crohn's disease,
             Colitis, IBD, Meckel's Diverticulum, Bowen Hernia, Mega Colon, fistulas or other
             strictures (doctors' discretion).

          -  Subject with known motility disorder or Chronic Constipation

          -  Subject with known delayed gastric emptying

          -  Subject with prior history of abdominal surgery that might cause bowel strictures
             leading to capsule retention, as determined by physician discretion

          -  Subject with any condition believed to have an increased risk for capsule retention
             such as intestinal tumors, radiation enteritis, and incomplete colonoscopies due to
             obstructions or NSAID enteropathy, as determined by physician discretion

          -  Subject with a cardiac pacemaker or other implanted electro medical device

          -  Subjects with known sensitivity to iodine, or with kidney failure

          -  Subjects with morbid obesity (BMI &gt; 40)

          -  Subject with any known condition which precludes compliance with study and/or device
             instructions

          -  Subject with known condition of drug abuse and/or alcoholism

          -  Subject who is unable to undergo colonoscopy or bowel preparation necessary for
             colonoscopy (based on previous attempts or self-declaration)

          -  Women who are either pregnant or nursing at the time of screening (to be verified by
             test in case of woman of child-bearing potential that do not practice medically
             acceptable methods of contraception)

          -  Concurrent participation in another clinical trial using any investigational drug or
             device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shlomo Lewkowicz, D.Sc.</last_name>
    <phone>+972-52-4747234</phone>
    <email>shlomo.lewkowicz@chec-cap.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hedva Taanach, RN B.Sc.</last_name>
    <phone>+972-52-5380377</phone>
    <email>hedva.taanach@check-cap.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadir Arber, Prof.</last_name>
      <phone>+972-3-6974968</phone>
      <email>nadira@tlvmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>November 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>average risk CRC screening</keyword>
  <keyword>Non compliant patients for CRC screening</keyword>
  <keyword>Counterindicated patients for colonoscopy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
